Table 5.

Multivariable logistic regression models evaluating the association between alcohol use and absence of liver fibrosis (FIB-4 <1.45) stratified by antiretroviral therapy use and by presence of Hepatitis B surface antigen (HBsAg) status

Variable	Adjusted odds ratio (95% IC) for absence of liver fibrosis	p-value
Antiretoviral therapy.
Lifetime alcohol consumption [kg. of alcohol] (n=175)
<150 kg.	1	0.70
150–600 kg.	1.17 (0.43, 3.17)
>600 kg.	1.45 (0.48, 2.24)
No antiretoviral therapy.
Lifetime alcohol consumption [kg. of alcohol] (n=116)
<150 kg.	1	0.86
150–600 kg.	1.25 (0.27, 5.85)
>600 kg.	0.93 (0.21, 4.04)
HBsAg positive
Lifetime alcohol consumption [kg. of alcohol] (n=24)
<150 kg.	1	0.14
150–600 kg.	0.27 (0.01, 6.62)
>600 kg.	0.04 (0.00, 1.67)
HBsAg negative
Lifetime alcohol consumption [kg. of alcohol] (n=259)
<150 kg.	1	0.87
150–600 kg.	1.26 (0.50, 3.17)
>600 kg.	1.22 (0.53, 2.85)